



Coverage Guidelines: Enbrel (etanercept)

Policy

Network Health covers Enbrel (etanercept) with prior authorization for *Network Health Together*[®], *Network Health Forward*[®], and *Network Health Extend* members who meet specific coverage criteria. Enbrel is only available through our specialty pharmacy program as a pharmacy benefit.

Covered conditions

Network Health covers Enbrel when a member meets all criteria for one of the following conditions:

Ankylosing spondylitis

- Is 18 years of age or older, **and**
- Has been evaluated by a rheumatologist, **and**
- Has tried and failed treatment with or has a contraindication to one nonsteroidal anti-inflammatory drug (NSAID); **or** has tried and failed treatment with another biological agent, such as Humira, Simponi, or Remicade; **or** is a new Network Health member already stabilized on Enbrel treatment

Juvenile rheumatoid arthritis

- Is between 2 and 17 years of age, **and**
- Has been evaluated by a rheumatologist, **and**
- Has tried and failed treatment with or has a contraindication to one traditional DMARD, such as azathioprine, gold therapy, hydroxychloroquine, methotrexate, penicillamine, sulfasalazine, cyclosporine, or leflunomide; **or** has tried and failed treatment with another biological agent, such as Humira; **or** is a new Network Health member already stabilized on Enbrel treatment

Plaque psoriasis

- Is 18 years of age or older, **and**
- Has been evaluated by a dermatologist, **and**
- Has tried and failed treatment with or has a contraindication to at least two of the following therapies: PUVA or UVB phototherapy, acitretin, cyclosporine, or methotrexate; **or** has tried and failed treatment with another biological agent, such as Humira, Amevive, or Remicade; **or** is a new Network Health member already stabilized on Enbrel treatment

These guidelines apply to *Network Health Together*, *Network Health Forward*, and *Network Health Extend* plans. Coverage is based on member benefits and eligibility; medical necessity review, where applicable; and the Network Health provider agreement. Adherence to these guidelines by a provider does not guarantee coverage. Network Health reserves the right to amend these guidelines at its discretion.



Psoriatic arthritis

- Is 18 years of age or older, **and**
- Has been evaluated by a rheumatologist or dermatologist, **and**
- Has tried and failed treatment with or has a contraindication to one traditional DMARD, such as azathioprine, gold therapy, hydroxychloroquine, methotrexate, penicillamine, sulfasalazine, cyclosporine, or leflunomide; **or** has tried and failed treatment with another biological agent, such as Humira, Simponi, or Remicade; **or** is a new Network Health member already stabilized on Enbrel treatment

Rheumatoid arthritis

- Is 18 years of age or older, **and**
- Has been evaluated by a rheumatologist, **and**
- Has tried and failed treatment with or has a contraindication to one traditional disease-modifying antirheumatic drug (DMARD), such as azathioprine, gold therapy, hydroxychloroquine, methotrexate, penicillamine, sulfasalazine, cyclosporine, or leflunomide; **or** has tried and failed treatment with another biological agent, such as Orenzia, Humira, Kineret, Cimzia, Simponi, or Remicade; **or** is a new Network Health member already stabilized on Enbrel treatment

Please note: Network Health will approve one year of initial Enbrel treatment if a member meets all of the initial criteria for a covered condition described in the covered conditions section. Network Health will continue to approve Enbrel treatment on an annual basis for these conditions when a provider provides clinical documentation (e.g., office note, specialist note) of member improvement while receiving Enbrel.

Noncovered conditions

Network Health does not cover Enbrel for conditions not described in the covered conditions section.

Definitions

Ankylosing spondylitis is a chronic inflammatory arthritis that affects the joints in the spine and the sacroiliac in the pelvis, and causes the vertebrae in the spine to fuse eventually.

Juvenile rheumatoid arthritis is a chronic and progressive disease in which the immune system attacks the joints. This disease is characterized by pain, inflammation, and swelling of the joints; stiffness; weakness; loss of mobility; and deformity. The onset occurs before age 16.

Plaque psoriasis is a type of psoriasis characterized by red, silvery-white, and scaly skin lesions.

Psoriatic arthritis is a form of rheumatoid arthritis associated with psoriasis that usually affects fingers and toes.

These guidelines apply to *Network Health Together*, *Network Health Forward*, and *Network Health Extend* plans. Coverage is based on member benefits and eligibility; medical necessity review, where applicable; and the Network Health provider agreement. Adherence to these guidelines by a provider does not guarantee coverage. Network Health reserves the right to amend these guidelines at its discretion.



Rheumatoid arthritis is a chronic and progressive disease in which the immune system attacks the joints. This disease is characterized by pain, inflammation, and swelling of the joints; stiffness; weakness; loss of mobility; and deformity.

Guidelines references

Enbrel [package insert]. (2008). *Immunex Corp.*

Haskes, P. J. & Laxer, R. M. (2005). Medical treatment of juvenile idiopathic arthritis. *Journal of the American Medical Association*. 294, 1671 – 1684.

Menter, A., Gottlieb, A., Korman, N. J., Gordon, K. B., Feldman, S. R., Lebwohl, M., Koo, J. Y. M., Van Voorhees, A. S., Elmets, C. A., Leonardi, C. L, Beutner, K. R., & Bhushan, R. (2008). Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. *Journal of the American Academy of Dermatology*. 58 (5), 826 – 850.

Menter, A., Gottlieb, A., Korman, N. J., Gordon, K. B., Feldman, S. R., Lebwohl, M., Koo, J. Y. M., Van Voorhees, A. S., Elmets, C. A., Leonardi, C. L, Beutner, K. R., & Bhushan, R. (2008). Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: Overview and guidelines of care for the treatment with an emphasis on biologics. *Journal of the American Academy of Dermatology*. 58 (5), 851 – 864.

Saag, K. G., Teng, G. G., Patkar, N. M., Anuntiyo, J., Finney, C., Curtis, J. R., Paulus, H. E., Mudano, A., Pisu, M., Elkins-Melton, M., Outman, R., Allison, J. J., Almazor, M. S., Bridges, Jr., S. L., Chatham, W. W., Hochberg, M., MacLean, C., Mikuls, T., Moreland, L. W., O’Dell, J., Turkiewicz, A. M., & Furst, D. E. (2008). American College of Rheumatology recommendations for the use of nonbiological and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. *Arthritis & Rheumatism*. 59 (6), 762 – 784.

Zochling, J., van der Heijde, D., Burgos-Vargas, R., Collantes, E., Davis, Jr., J. C., Dijkmans, B., Dougados, M., Géher, P., Inman, R. D., Khan, M. A., Kvien, T. K., Leirisalo-Repo, M., Olivieri, I., Pavelka, K., Sieper, J., Stucki, G., Sturrock, R. D., van der Linden, S., Wendling, D., Böhm, H., van Royen, B. J., & Braun, J. (2006.) ASAS/EULAR recommendations for the management of ankylosing spondylitis. *Annals of the Rheumatic Diseases*. 65, 442.

These guidelines apply to *Network Health Together*, *Network Health Forward*, and *Network Health Extend* plans. Coverage is based on member benefits and eligibility; medical necessity review, where applicable; and the Network Health provider agreement. Adherence to these guidelines by a provider does not guarantee coverage. Network Health reserves the right to amend these guidelines at its discretion.